Management of superficial and deep surgical site infection: an international multidisciplinary consensus

Gabriele Sganga1 · Mohamed Baguneid2,3,4 · Pascal Dohmen5,6 · Evangelos J. Giamarellos-Bourboulis7 · Emilio Romanini8 · Athanassios Vozikis9 · Christian Eckmann10

Received: 31 December 2020 / Accepted: 11 March 2021 / Published online: 26 March 2021 © The Author(s) 2021

Abstract
Surgical site infections represent a considerable burden for healthcare systems. To obtain a consensus on the impact and future clinical and economic needs regarding SSI management in an era of multidrug resistance. A modified Delphi method was used to obtain consensus among experts from five European countries. The Delphi questionnaire was assembled by a steering committee, verified by a panel of experts and administered to 90 experts in 8 different surgical specialities (Abdominal, Cancer, Cardiac, General surgery, Orthopaedic, Thoracic, Transplant and Vascular and three other specialities (infectious disease, internal medicine microbiology). Respondents (n = 52) reached consensus on 62/73 items including that resistant pathogens are an increasing matter of concern and increase both treatment complexity and the length of hospital stay. There was strong positive consensus on the cost-effectiveness of early discharge (ED) programs, improvement of quality of life with ED and association between increased length of stay and economic burden to the hospital. However, established ED protocols were not widely available in their hospitals. Respondents expressed a positive consensus on the usefulness of antibiotics that allow ED. Surgeons are aware of their responsibility in an interdisciplinary team for the treatment of SSI, and of the impact of multidrug-resistant bacteria in the context of SSI. Reducing the length of hospital stays by applying ED protocols and implementing new treatment alternatives is crucial to reduce harm to patients and costs for the hospital.

Keywords Surgical site infection · Management · Antimicrobial

Abbreviations
AMR Antimicrobial-resistance
CI Confidence interval
ECDC The European Centre for Disease Prevention and Control
ED Early discharge
LOS Length of (hospital) stay
MRSA Methicillin-resistant Staphylococcus aureus
MSSA Methicillin-sensitive Staphylococcus aureus
SSI Surgical site infection
UI Uncertainty interval
US CDC US Centers for Disease Control and Prevention

1 Division of Emergency Surgery and Trauma, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
2 School of Medical Sciences, University of Manchester, Manchester, UK
3 Surgical Institute, Al Ain Hospital, Al Ain, United Arab Emirates
4 College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates
5 Department of Cardiac Surgery, Heart Center Rostock, University Medicine Rostock, Rostock, Germany
6 Department of Cardiac Surgery Faculty of Health Science, University of the Free State, Bloemfontein, South Africa
7 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece
8 RomaPro Center for Hip and Knee Arthroplasty, Polo Sanitario San Feliciano, Via Enrico De Ossò 6, Rome, Italy
9 Laboratory of Health Economics and Management, University of Piraeus, Piraeus, Greece
10 Department of General, Visceral and Thoracic Surgery, Klinikum Hannoversch-Muenden, Goettingen University, Göttingen, Germany
Introduction

Despite proper precautions, surgical site infections (SSI) remain a major challenge, comprising 18.4% of all acute care-associated infections, an incidence similar to that of hospital-acquired pneumonia or urinary tract infections [1], and result in an estimated 16,049 deaths per year [2]. The incidence of SSIs is projected to increase as an aging population and increasing obesity lead to more procedures [3].

The risk of SSI varies according to type and duration of surgery, with a higher risk in emergency and/or intra-abdominal surgery involving penetration of hollow viscera, and substantially lower risk in other types of surgery (orthopaedic, cardiothoracic, vascular, neurosurgery) [4, 5]. Immunosuppressed, obese and diabetic patients are also at higher risk [6, 7].

Causative pathogens are usually commensal bacteria associated with the surgical site [8], and thus tend to vary according to the procedure [9]. When organisms are isolated, the most frequently identified bacteria include Staphylococcus aureus, coagulase-negative Staphylococci, Enterococcus sp., and Escherichia coli [10, 11]. Whereas Gram-positive microorganisms like S. aureus are the most common causative pathogens, Gram-negative bacteria including Enterobacteriaceae may cause SSIs, especially after abdominal procedures. Another element of variability is the risk of infection with antimicrobial-resistant (AMR) bacteria. SSIs involving AMR pathogens are associated with significant increases in the length of hospitalization and costs [12].

Institutional infection surveillance reports are the most relevant source of information [13], and their existence has been shown to reduce SSI rates [14]. Accurate estimation of SSI rates is hindered when onset occurs after discharge [15, 16]. Meta analysis of data from 1.4 million surgeries in 15 countries identified 141,347 SSIs, of which 84,984 (60.1%) appeared after discharge [17]. Recently, a patient-self-assessment questionnaire has been validated for assessing SSIs after hospital discharge [18].

The multidisciplinary team is responsible for stratifying SSI risk and coordinating surgical and antimicrobial approaches for treating infections [19]. Therefore, members should be familiar with local epidemiology, antimicrobial resistance, and the available antimicrobial options. Reliable data on clinicians’ perspectives on SSI management are lacking. To this end, we have conducted a modified Delphi process to develop an expert consensus on the management of superficial and deep incisional SSIs from a large panel of experts working in different specialties and European countries.

Methods

Delphi method

We used a modified Delphi process to obtain consensus among 52 European experts on the management of surgical site infection [20]. The process was conducted by a 7-member multinational steering committee comprising Surgeons (Cardiac, General and Emergency, Orthopaedic, Thoracic and Vascular), an Infectious Disease expert and a Health Economics expert (the Authors) assembled and led by C.E. and G.S. Each committee member prepared candidate Delphi questionnaire statements in their area of expertise based on their experience and familiarity with the literature and guidelines. These candidate statements were presented and discussed at an organisational meeting in Rome on June 14, 2019. The draft questionnaire was submitted to a round of validation by a panel of 8 experts identified by the steering committee (Listed in acknowledgements section). The validation panel provided feedback on the legibility and coherence of the statements. The final revised version contains 15 statements with a total of 73 items divided among 4 SSI topics (Epidemiology, Management, Consequences, and Antimicrobial therapy approach) (Appendix I—Supplemental File 1).

In addition to the consensus items, the questionnaire contained items to survey the respondents’ level of expertise, local epidemiology and the medical setting that they work in. This ancillary information was used when interpreting the consensus items. The questionnaire asked experts to indicate their level of agreement with each item on a 5-point Likert scale, in which 1-strongly disagree, 2-disagree, 3-agree, 4-more than agree, 5-strongly agree. It was determined a priori that responses of 1–2 would be considered disagreement, whereas responses of 3–5 would be considered agreement, and that consensus would be defined as ≥66% agreement/disagreement. This was explained in the instructions for competing the questionnaire.

The questionnaire was distributed electronically to a purposive sample of 90 surgeons in 5 European countries (France, Germany, Greece, Italy and the UK), which was identified by the steering committee based on their contributions in the field (e.g., national/international leadership, publications, work on commissions). Participating experts expressed their opinions anonymously, in accordance with Delphi methodology. Responses were analysed and discussed by the steering committee at a second meeting in Rome on October 22, 2019.

Definition of an SSI

For the purpose of this consensus, we have considered superficial and deep incisional infections occurring after an
index surgery (Appendix 2—Supplemental File 2), according to the US Centers for Disease Control and Prevention (US CDC) definition [21, 22]. For deep incisional infections, we considered only major abscesses and deep cellulitis. Organ/space infections (US CDC classification A3) were not included in this consensus as they could be confounded by complications not related to measures for the reduction of SSI (e.g., anastomotic leakage).

Results

Participants

Of 90 surveys distributed, 52 experts responded (58%). Respondents were evenly distributed between Western and South-eastern Europe. Respondents were practicing in France (1), Germany (12), Greece (15), Italy (12), or United Kingdom (12), and comprised 36 surgeons from 8 major specialties and 16 infectious disease experts (Appendix III—Supplementary Table 1).

Consensus was achieved on 62 of 73 items. The remaining 11 items (15%) did not reach consensus; however, most of these were ancillary items that had been included for ascertaining the respondents’ expertise, local epidemiology and clinical setting; therefore, a consensus would not be expected/appropriate on these items. As such, they were not addressed in a further Delphi round but commented on as useful insight into possible differences among geographic areas and different surgical specialties.

Delphi results

Epidemiology (Fig. 1)

Statement 1.1: SSI epidemiology We sought to confirm that the experts do indeed face this problem on a regular basis, therefore, the strong agreement on item 1.1.1 indicates that they self-identity as experts in this area. They rely on both personal experience (item 1.1.3) and local/national databases as a source of information on SSI frequency (item 1.1.4); they agree also that superficial SSIs can increase LOS (item 1.1.5). Meanwhile, only half of the experts indicated that superficial SSIs are frequently referred to them (item 1.1.2).

Statement 1.2: SSI microbiology Considering the microbiology of SSIs in their facilities, respondents agreed that Staphylococcus aureus is the most common pathogen (item 1.2.1); however only half of the respondents agreed that MRSA is frequent in their setting (item 1.2.2). There was agreement that Gram-negative pathogens were frequent causes of SSIs (item 1.2.3), and that coagulase-negative Staphylococcus spp. can cause SSIs (item 1.2.4).

Statement 1.3: Antimicrobial resistance in SSI Respondents strongly agree that resistant pathogens are an increasing matter of concern in SSIs (item 1.3.1), that they increase both treatment complexity (item 1.3.2), and LOS (item 1.3.3). With respect to their own practices, only half of the experts indicated that MRSA is a frequent cause of SSIs (item 1.3.4); whereas 52% considered Gram-negative MDR bacteria to be the organisms most frequently isolated in SSIs (item 1.3.5).

Management (Fig. 2)

Statement 2: Main principles of management Regarding the management of patients with acute bacterial SSIs, there was a weak positive consensus that testing should be performed to exclude osteomyelitis (item 2.1.1). Respondents agreed that the decision to perform surgical drainage should be based mainly on clinical assessment (item 2.1.2); there was also agreement on the need to collect material from an infected wound for culture (item 2.1.2); and on requesting molecular testing for MRSA (item 2.1.4); also, most experts agreed on the need to perform incision and drainage in superficial skin infections (item 2.1.5). There was no consensus on the need to modify the treatment algorithm for patients with diabetes mellitus type 2 (item 2.1.6).

Consequences (Fig. 3)

Statement 3.1: Clinical management of SSI Respondents strongly agree that infection with resistant bacteria increases the time that Health Care Professionals spend with patients (item 3.1.1) and that isolation precautions for SSIs due to MRSA cause anxiety and additional psychological burden for affected patients (item 3.1.2). Only 56% confirmed that ED protocols are available in their hospitals (item 3.1.3); however, there was agreement that hospital admissions and discharges are usually well organized (item 3.1.4), while the organization of admission and discharge in acute wards is a major problem (item 3.1.5). There was strong agreement that prolonged indwelling intravenous devices for drug administration increase the risk of infections with resistant organisms (item 3.1.6).

Statement 3.2: Choice of antibiotics The group consensus was consistently negative on the four items concerning the use of narrow-spectrum antimicrobials: covering
### 1.1 Surgical Site Infections (SSIs) are a common problem for the surgeon

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|--------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 1.1.1 I deal with these types of patients daily                         |              |                      |           |
| 1.1.2 Patients with superficial infections are seldom referred to me    | 50%          | 7 9 15 21             | 87%       |
| 1.1.3 My perception on the frequency of SSIs is based on my personal experience |              |                      |           |
| 1.1.4 My perception on the frequency of SSIs is based on local/national databases |              |                      |           |
| 1.1.5 Superficial SSIs (AI) increase the hospital Length of Stay (LoS)   | 35%          | 4 8 17 22             | 90%       |

### 1.2 Regarding the microbiology of SSIs in my facility:

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|--------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 1.2.1 Staphylococcus aureus is the most common pathogen                   | 50%          | 3 13 12 16 8          | 69%       |
| 1.2.2 Staphylococcus aureus is often resistant to methicillin in my setting |              |                      |           |
| 1.2.3 Gram-negative bacteria are a frequent cause of SSIs               | 50%          | 7 19 15 8 5           | 50%       |
| 1.2.4 I believe that coagulase-negative Staphylococcus spp. can cause SSI |              |                      |           |

### 1.3 Concerning resistant pathogens in SSIs:

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|--------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 1.3.1 Resistant pathogens in SSIs are an increasing matter of concern    |              |                      |           |
| 1.3.2 Resistant pathogens in SSIs increase the complexity of treatment   |              |                      |           |
| 1.3.3 Confirmation of resistant pathogens in SSI increases the LoS        |              |                      |           |
| 1.3.4 MRSA is a frequent cause of SSIs in my practice                   | 50%          | 6 20 13 11 2          | 50%       |
| 1.3.5 Gram-negative MDR bacteria are the organisms most frequently isolated in SSIs | 48%          | 9 16 15 8 4          | 52%       |

**Fig. 1** Percentage of agreement and number of respondents on each statement of the Delphi questionnaire. Topic 1: Epidemiology

### 2.1 When I manage patients with acute bacterial SSIs

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|--------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 2.1.1 I seldom test to exclude osteomyelitis                             |              |                      |           |
| 2.1.2 My decision to perform surgical drainage depends more on my clinical assessment than any one specific investigation |              |                      |           |
| 2.1.3 I always collect material from the site of infection for culture  |              |                      |           |
| 2.1.4 I want the microbiology lab to perform molecular testing for meticillin-resistant Staphylococcus aureus |              |                      |           |
| 2.1.5 I often perform incision and drainage in superficial skin infections |              |                      |           |
| 2.1.6 My treatment algorithm changes if the patient has diabetes mellitus type 2 | 37%          | 15 18 12 13           | 63%       |

**Fig. 2** Percentage of agreement and number of respondents on each statement of the Delphi questionnaire. Topic 2: Management
### Fig. 3  Percentage of agreement and number of respondents on each statement of the Delphi questionnaire. Topic 3: Consequences

| 3.1 Regarding the clinical management of SSIs | Disagreement | Number of respondents | Agreement |
|---------------------------------------------|--------------|-----------------------|-----------|
| 3.1.1 Infection with resistant bacteria increases the time HCPs spend with patients | 4 6 30 | 13 | 92% |
| 3.1.2 Isolation precautions for SSI due to MRSA cause anxiety and other psychological burden to affected patients | 8 7 27 | 10 | 85% |
| 3.1.3 Early discharge protocols are available in my hospital | 6 17 8 12 9 | 56% |
| 3.1.4 The admission and discharge processes are usually well organized | 4 13 17 14 2 | 67% |
| 3.1.5 Organization of admission and discharge is a major problem on acute wards | 2 11 11 21 7 | 75% |
| 3.1.6 The prolonged indwelling of intravenous devices for drug administration increases the risk of infections relating to resistant organisms | 2 8 22 20 | 96% |

| 3.2 When choosing an antibiotic treatment... | Disagreement | Number of respondents | Agreement |
|---------------------------------------------|--------------|-----------------------|-----------|
| 3.2.1 I tend to cover only methicillin-resistant Staphylococcus aureus | 85% | 13 31 6 2 | 85% |
| 3.2.2 I always give a combination to cover both Gram-positive cocci and Gram-negative bacteria | 85% | 11 33 7 1 | 85% |
| 3.2.3 In cases where a patient has taken antibiotics in the last 90 days, I cover only methicillin-resistant Staphylococcus aureus | 85% | 7 23 19 4 | 85% |
| 3.2.4 My choice of antibiotic treatment differs if the infection is hospital-acquired | 87% | 2 6 12 26 6 | 87% |
| 3.2.5 If the infection is hospital-acquired, I cover only Gram-negative bacteria | 87% | 2 10 24 6 2 | 87% |
| 3.2.6 Methicillin-resistant Staphylococcus aureus is the only pathogen of concern in patients on chronic hemodialysis | 85% | 14 15 19 8 | 85% |
| 3.2.7 Patients with liver cirrhosis should be treated differently | 85% | 14 15 19 8 | 85% |

| 3.3 Antibiotic treatment for patients with SSIs | Disagreement | Number of respondents | Agreement |
|---------------------------------------------|--------------|-----------------------|-----------|
| 3.3.1 When drainage is not required, I empirically prescribe antibiotic treatment for 14 days | 62% | 13 19 8 11 5 | 38% |
| 3.3.2 When drainage is required, I perform the surgery and then prescribe empirical antibiotic treatment for 14 days | 65% | 14 20 6 11 5 | 35% |
| 3.3.3 I re-evaluate my patient 3 days after the starting antibiotic treatment | 8 27 15 | 96% |
| 3.3.4 If the patient has not improved after 3 days, I change the antibiotic treatment | 14 15 17 3 | 71% |
| 3.3.5 Improvement after 3 days is evaluated based on patient’s vital parameters | 13 21 15 3 | 71% |
| 3.3.6 Improvement after 3 days is evaluated based on a decrease in skin lesion dimensions | 14 18 24 5 | 90% |

| 3.4 Regarding the economic consequences of SSIs, I believe that... | Disagreement | Number of respondents | Agreement |
|---------------------------------------------|--------------|-----------------------|-----------|
| 3.4.1 Early discharge programs for patients with SSI are cost-effective (in terms of potential bed savings, and of reductions in both hospital acquired infections and costs) | 2 8 26 4 16 | 96% |
| 3.4.2 Early discharge programs for patients with SSIs add value through improvement of patients’ QoL and satisfaction | 2 7 26 17 4 | 96% |
| 3.4.3 Increased LOS causes economic burden to the hospital | 8 17 23 3 | 98% |
| 3.4.4 SSIs involving resistant pathogens are associated with increased medical service utilisation, compared to SSIs involving susceptible pathogens | 8 20 27 19 9 | 98% |
| 3.4.5 The additional time that HCPs spend with patient with MRSA-SSI increases the economic burden | 8 24 19 9 | 98% |
only MRSA (item 3.2.1); covering only MRSA in patients who have taken antibiotics in the last 90 days (item 3.2.3), covering only Gram-negative bacteria in hospital-acquired infections (item 3.2.5), and covering only MRSA in patients on chronic haemodialysis (item 3.2.6). On the other hand, respondents agreed on the need to administer regimens that cover both Gram-positive cocci and Gram-negative bacteria (item 3.2.2), and that the antimicrobial treatment choice differs if the infection is hospital-acquired (3.2.4) and if patient has liver cirrhosis (item 3.2.7).

**Statement 3.3: Antibiotic treatment for patients with SSIs** There was no consensus on whether empirical antibiotic treatment should be prescribed for 14 days, irrespective of whether drainage is required (items 3.3.1 and 3.3.2). There was positive consensus on the four items dealing with wound assessment 3 days after starting antibiotic treatment: re-evaluation after 3 days (3.3.3), changing the antibiotic treatment if there is no improvement (3.3.4), evaluating response to treatment based on the patient’s vital parameters (3.3.5), and evaluation based on a decrease in skin lesion dimensions (3.3.6).

**Statement 3.4: Regarding the economic consequences of SSI** There was strong positive consensus on all five items concerning the economic consequences of SSI: cost-effectiveness of ED programs (3.4.1), improvement of quality of life with ED (3.4.2), association between increased length of stay and economic burden to the hospital (3.4.3), increased service utilization for SSIs caused by resistant microorganisms, (3.4.4), and increased healthcare professional workload when SSIs involve MRSA (3.4.5).

**Antibiotic therapy approach (Fig. 4)**

**Statement 4.1: Ideas on the ideal antibiotic therapy** Considering the ideal antimicrobial therapy to treat SSIs, respondents strongly agreed on the following characteristics: efficacy and safety established in randomized controlled trials (4.1.1), few drug-to-drug interactions and side-effects (4.1.2); coverage of MSSA and offer empirical coverage of MRSA (4.1.3), and coverage of Gram-negative resistant bacteria in high-risk surgical patients (4.1.4). These characteristics are linked with ED (4.1.5).

**Statement 4.2: Prescription principles** When considering important antibiotic prescription principles, respondents expressed a positive consensus for antibiotics that allow ED while instilling confidence that the patient has appropriate coverage in the outpatient setting. Most respondents were concerned about the cost of antibiotics (4.2.2) and about side effects (4.2.4); nearly one third of clinicians (31%) were not willing to risk outpatient treatment for SSIs in uncomplicated patients (4.2.3).

**Statement 4.3: Route of antibiotic administration** Respondents agree that strict adherence is important for early treatment responses (4.3.4), that a single infusion covering the entire treatment course for SSI would improve adherence (4.3.1) and that switching to oral treatment for several days improves adherence (4.3.2). They did not agree that multiple (intermittent) daily infusions improve adherence (4.3.3).

**Statement 4.4: Improving compliance** Respondents agreed that adherence to antibiotics for SSI can be improved with short-course oral therapy (4.4.1). There was a positive consensus that the use of long-acting antibiotics improves adherence (4.4.2) and allow ED (4.4.3), and that one single infusion that covers the full treatment course reduces the need for peripheral or central lines in antibiotic treatment of SSI (4.4.4).

**Statement 4.5: Evidence-based properties of long-acting anti-Gram-positive/MRSA antibiotics** There was positive consensus that all of the following evidence-based properties of a long-acting anti-Gram-positive/MRSA antibiotic are relevant: plasma levels maintained for at least 14 days after one single injection (4.5.1); high activity on all Gram-positive SSI pathogens including MRSA (4.5.2), early signs of treatment response after 48–72 h (4.5.3) and no need for renal or haematological monitoring (4.5.4).

**Statement 4.6: Settings for long-acting anti-Gram-positive/MRSA antibiotics** Regarding settings where long-acting anti-Gram-positive/MRSA antibiotics may be beneficial, there was no consensus for first-line empirical therapy (4.6.1), or for bacteraemia detected in closed SSIs (4.6.3). There was a positive consensus for rescue therapy when previous “appropriate” antibiotic therapies fail (4.6.2) and at the first sign of infection in surgical wounds with implants, to avoid deepening of the infection (4.6.4).

**Statement 4.7: Patient profile for long-acting anti-Gram-positive/MRSA antibiotic treatments** There was positive consensus that patient suitable for long-acting anti-Gram-positive/MRSA antibiotic treatments should be stable after SSI drainage and otherwise candidates to be discharged home (4.7.1), patients at risk of poor treatment compliance (4.7.2), stable patient with SSI and concomitant cellulitis who can otherwise be discharged home (4.7.3) and patients with SSI at high risk of MRSA infection (4.7.4).
Fig. 4 Percentage of agreement and number of respondents on each statement of the Delphi questionnaire. Topic 4: Antibiotic therapy approach

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|---------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 4.1 The ideal antibiotic therapy to treat SSI should:                     |              |                       |           |
| 4.1.1 Have proven efficacy and safety in randomized controlled trials     | 7            | 20                    | 22        | 100%      |
| 4.1.2 Have few drug-drug interactions and side-effects                   | 4            | 27                    | 13        | 94%       |
| 4.1.3 Cover MSSA and other empirical coverage of MRSA                    | 1            | 12                    | 25        | 87%       |
| 4.1.4 Cover Gram-negative resistant bacteria in high risk surgical patients | 3            | 97                    | 27        | 94%       |
| 4.1.5 Allow early discharge                                              | 8            | 22                    | 21        | 99%       |

4.2 The following antibiotic prescription principles are important to me

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|---------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 4.2.1 I want to prescribe an antibiotic that allows early discharge and to be confident that the patient has the right coverage in outpatient setting | 3            | 17                    | 29        | 100%      |
| 4.2.2 I am concerned about the cost of antibiotics                       | 8            | 8                     | 22        | 74%       |
| 4.2.3 I am not willing to risk out-patient treatment of SSI for uncomplicated patients | 12           | 24                    | 6         | 69%       |
| 4.2.4 I am concerned about side effects                                  | 5            | 6                     | 8         | 85%       |

4.3 Considering the route of antibiotic administration in SSI:

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|---------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 4.3.1 A single infusion that covers the entire treatment course for SSI would improve adherence | 9            | 21                    | 10        | 100%      |
| 4.3.2 Switching to oral treatment for several days improves adherence     | 7            | 14                    | 10        | 71%       |
| 4.3.3 Multiple (intermittent) daily infusions improve adherence           | 10           | 32                    | 6         | 91%       |
| 4.3.4 Strict adherence matters for early treatment responses              | 6            | 35                    | 3         | 96%       |

4.4 In order to improve adherence of patients to antibiotics for SSI:

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|---------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 4.4.1 Short course oral therapy could be an option                        | 4            | 13                    | 28        | 90%       |
| 4.4.2 Long-acting antibiotics improve adherence to treatment              | 3            | 9                     | 24        | 88%       |
| 4.4.3 Long-acting antibiotics can be used in order to allow early discharge | 3            | 13                    | 25        | 93%       |
| 4.4.4 One single infusion that covers the full course of treatment reduces the need for peripheral or central lines in antibiotic treatment of SSI | 4            | 22                    | 30        | 92%       |

4.5 The following evidence-based properties of a long-acting anti-Gram-positive/MRSA antibiotic are relevant:

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|---------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 4.5.1 After one single injection, trough levels are maintained for at least 14 days | 9            | 16                    | 22        | 75%       |
| 4.5.2 It is highly active on all Gram-positive SSI pathogens, including MRSA | 10           | 26                    | 11        | 92%       |
| 4.5.3 Early signs of treatment benefit in SSI are evident after 48 to 72 hours | 1            | 13                    | 27        | 98%       |
| 4.5.4 No need or haematological monitoring is required                    | 14           | 9                     | 17        | 67%       |

4.6 I believe the properties attributed to a long-acting anti-Gram-positive/MRSA antibiotic may be beneficial in the following cases

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|---------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 4.6.1 As first line empirical therapy                                     | 5            | 22                    | 10        | 48%       |
| 4.6.2 When previous "appropriate" antibiotic therapy fails                | 11           | 13                    | 23        | 73%       |
| 4.6.3 In case of bacteremia detected during diagnostic procedures in closed SSI | 18           | 13                    | 16        | 93%       |
| 4.6.4 In case of early surgical wound infection with implants at the first signs of infection to avoid deepening of the infection | 12           | 13                    | 20        | 92%       |

4.7 Patient profile for a long-acting anti-Gram-positive/MRSA antibiotic treatment should include:

| Statement                                                                 | Disagreement | Number of respondents | Agreement |
|---------------------------------------------------------------------------|--------------|-----------------------|-----------|
| 4.7.1 Stable patient after drainage of SSI who can otherwise be discharged home | 7            | 8                     | 28        | 95%       |
| 4.7.2 A patient at risk of poor treatment compliance (e.g., dementia, IV drug users) | 7            | 28                    | 17        | 93%       |
| 4.7.3 Stable patient with SSI and comorbidities who can otherwise be discharged home | 4            | 13                    | 24        | 92%       |
| 4.7.4 A patient with SSI and high risk of MRSA infection (e.g., liver dysfunction, chronic haemodialysis, previous MRSA colonisation) | 9            | 5                     | 26        | 93%       |
Discussion

This Delphi process revealed that the participating European experts were aware of the burden of SSIs since consensus was achieved in the great majority of items. Experts do consider MRSA and resistant Gram-negative bacteria as common pathogens, but they also recognize one emerging limitation that should be taken into consideration: the financial burden that may rise from prolonged hospitalization and the need for strategies to promote ED.

Responses on epidemiology are consistent with ECDC surveillance data [23]. Respondents agreed almost unanimously on the importance of collecting samples from SSIs for microbiological analysis; three quarters of them would like their microbiology laboratories to perform molecular testing for MRSA.

As expected from a survey conducted across regions, there were different responses on the perceived frequency of MRSA in SSIs. This is consistent with surveillance data showing a mean incidence of MRSA in European countries of 16.4%, but a range from 0 to 43% [24]. About half of the respondents indicated that AMR Gram-negative bacteria are the most frequent SSI pathogens in their setting. This is consistent with results from 633 SSIs in a Greek study that found high rates of AMR associated with Gram-negative pathogens from skin infections [11].

Whereas the incidence of AMR Gram-negative infections is higher in several Southern and Eastern European countries [24, 25], it is not clear that these pathogens are implicated in a high percentage of SSIs. The response of our panel may reflect heightened awareness of the increasing burden imposed by AMR pathogens in any kind of infection. Each year in the EU and EEA alone they are estimated to cause 33,000 deaths and 874,000 disability-adjusted life years (DALYs) [26].

The lack of consensus on the duration of antimicrobial treatment reflects the ongoing debate. In general, shorter treatment durations may be safer and as effective for uncomplicated bacterial infections [27, 28]. Longer courses are appropriate for deep-seated or severe infections that require a treatment regimen with optimised pharmacokinetics and pharmacodynamics and may benefit from a treatment duration that is based on clinical response and biomarkers [29]. Recent endpoints for acute bacterial skin and skin structure infections propose early response criteria based on lesion size after 48–72 h [30]; in our survey, this is reflected in the consensus on the need to re-evaluate patients after 3 days.

These experts were aware of the substantial economic burden associated with SSIs, mainly due to increased LOS [31–33], and agreed that discharge protocols are important for dealing with this issue; however, the survey results on the availability of ED protocols (3.1.3) indicate they are used only sparsely. This confirms the results of a pan-European retrospective study in 1500 patients with complicated skin and soft-tissue infections due to MRSA conducted to identify the potential to switch from iv to oral antibiotic medication and facilitate ED. The mean length of stay in that study was almost 20 days and the potential for ED almost 40% [34]. While ED programs for appropriate patients can reduce hospital costs, they have the added advantages of reducing the risk of hospital-acquired infections [35].

There was a strong consensus that the ideal antibiotic therapy to treat SSIs should allow ED for otherwise eligible patients (4.1.5), while ensuring that they will have suitable antimicrobial coverage (4.2.1; 4.2.3). Strategies for achieving this include switching from iv to oral formulations or administering long-acting drugs that allow single shot or weekly administrations.

Compliance is a major determinant of therapeutic success [36]: however, adherence to oral antibiotic therapy after hospital discharge is suboptimal and may be associated with poor outcomes [37]. In further considerations on the route of administration, the panel expressed a consensus for using a single infusion covering the entire antimicrobial course (4.3.1) to improve adherence by avoiding the need for multiple (daily) dosing (4.3.3). This is consistent with the findings of a Delphi process conducted with 238 clinicians (61% infectious disease specialists) in 10 European countries, which showed a strong consensus on the importance of adherence and the advantages of administering long-acting drugs for acute bacterial skin and skin structures infections [38]. Long-acting lipoglycopeptide antimicrobials such as dalbavancin and oritavancin provide intrinsic treatment adherence due to their long half-lives [39].

The panel did not reach a consensus on the appropriateness of long-acting agents in the first-line empirical setting (4.6.1). This is consistent with the concerns regarding Gram-negative pathogens and preference for broad-spectrum coverage expressed in items (3.2). However, there was strong agreement that long-acting agents would be beneficial as a rescue treatment when a previous appropriate antimicrobial treatment fails (4.6.2) or in the context of preventing the deepening of an SSI that is associated with an implant (4.6.4). The profile for a patient with SSI to be treated with long-acting agents was that of a stable patient, possible after SSI drainage, possibly with concomitant cellulitis, who could otherwise be discharged home (4.7.1; 4.7.3). Other characteristics could include the risk of poor compliance and/or MRSA infection (4.7.2; 4.7.4).

This investigation has several strengths: To the best of our knowledge, this is the first publication to address the important global issue of SSI burden and treatment through a Delphi method among experts in the field. Moreover, it
comprises the consensus of a broad variety of surgical disciplines from five European countries. The high percentage of consensus reflects that clinicians are facing many of the same challenges, regardless of their specialty and nationality.

This study has several limitations. The Delphi process was confined to the steering committee which designed the questions and received feedback from a validation group of experts (see above). The validated questionnaire was administered to the Delphi group of international experts in the field of SSI only once. The objectivity of the results may have increased with an additional round; however, this strategy has been used successfully in other Delphi procedures with heterogeneous panels [9, 38, 40]. Secondly, the Delphi population was identified through purposive sampling based on the contributions of potential participants to the international literature and their professional reputations, with the aim of obtaining input from established experts in different specialties working in several European countries; this should be considered when interpreting the responses.

Conclusions

This Delphi process has revealed that experts are aware of their responsibility in an interdisciplinary team for the treatment of SSI. The issue of multidrug-resistant gram-positive and gram-negative bacteria causing SSI is well recognised, as well as the implications for the affected patients and the hospital. Reducing LOS while maintaining the same quality of care is an important aim in SSI, to reduce harm to the patients and costs for the hospital. Wider availability of early discharge protocols and the implementation of new treatment alternatives like long-acting antibiotics will be crucial for the optimal future management of SSI in an era of multidrug resistance.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s13304-021-01029-z.

Acknowledgements The Authors wish to thank Ethos srl for support in conducting the Delphi process. Validation panel members: Arnab Bhowmick, Sergio Colizza, Francesco Cortese, Ioannis Koutelidakis, Muntzer Mughal, Konstantinos Toutouzas, Gabriele Tucci, Gustavo Zanoli. Participants of the Delphi Process: Anthony Alozie, Anastasia Antoniadou, Nikolaos Arkadopoulos, Francesco Arone, Andrea Baldini, Jonathan Barker, Christian Binner, Ricky Bhogal, Gary Boland, Massimo Carlini, Grigoriios Chatzimavroudis, Massimo Chiarugi, Valerio Cozza, Finlay Curren, Nikolaos Danias, George Dimopoulos, Georgia Doulam, Shridhar Dronamraju, Luca Fattori, Pietro Fransvea, Efthymia Giannitsioti, Beatrice Grabein, Xavier Guirao, Tracey Irvine, Rainer Isenmann, Jean Yves Jenny, Abdullah Jibawi, Dimitra Kavatha, Hussein Khambalia, Peter Kujath, Antonio La Greca, Stefan Maier, Bart Meuris, Nikolaos Michalopoulos, Savino Occhionorelli, Antonios Papadopoulos, Mathias Pletz, Garyphalia Poulakou, Mina Psychogiou, Sergio Ribaldi, Holger Rohde, Matteo Runfola, Michael Samarkos, Helen Sambatakou, Hodjat Shekarriz, Simone Slawik, Spyridon Stergiopoulos, Sotirios Tsiodras, David van Dellen, Michael Wilke, Paul Wilson, Reza Zadeh.

Author contributions GS and CE conceived the project. All the authors drafted the manuscript. EGB made major revisions to the first draft. All the Authors contributed to formulating the questionnaire, analysing the responses, and made critical revisions of the manuscript.

Funding Open access funding provided by Università Cattolica del Sacro Cuore within the CRUI-CARE Agreement. This publication was supported by an unrestricted grant from Angelini.

Data availability “Not applicable”. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations

Conflict of interest Gabriele Sganga, Mohamed Baguneid, Pascal Dohmen, Emilio Romanini and Athanassios Vozikis declare no conflicts of interest. E.J. Giannarellos-Bourboulis has received honoraria from AbbVie USA, Abbott CH, Biotest Germany, Brahms GmbH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMérieux Inc, InflaRx GmbH, the Medicines Company and XBiotech Inc.; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). Christian Eckmann received honoraria for lectures and advisory boards from Angelini, Correvio, Nabriva, Merck and Pfizer.

Ethics approval and consent to participate “Not applicable”. Our manuscript does not report on, or involve the use of any animal or human data or tissue, and does not contain data from any individual person, so this section is not applicable to our submission.

Consent for publication “Not applicable”. Our manuscript does not contain data from any individual person, so this section is not applicable to our submission.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Suetens C, Latour K, Kärki T, RicchizzI E, Kinross P, Moro ML. The Healthcare-Associated Infections Prevalence Study Group
et al (2018) Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill 23:1800516. https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516

2. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Dumcombe T et al (2016) Burden of six healthcare-associated infections on European population health: estimating incidence-based disability-adjusted life years through a population prevalence-based modelling study. PLoS Med 13:e1002150. https://doi.org/10.1371/journal.pmed.1002150

3. Wolford HM, Hatfield KM, Paul P, Yi SH, Slayton RB (2018) The projected burden of complex surgical site infections following hip and knee arthroplasties in adults in the United States, 2020 through 2030. Infect Control Hosp Epidemiol 39:1189–1195. https://doi.org/10.1017/ice.2018.184

4. Gaynes RP (2000) Surgical-site infections and the NNIS SSI Risk Index: room for improvement. Infect Control Hosp Epidemiol 21:184–185

5. Lakomkin N, Sathiyakumar V, Wick B, Shen MS, Jahnagir AA, Mir H et al (2017) Incidence and predictive risk factors of postoperative sepsis in orthopedic trauma patients. J Orthop Traumatol 18:151–158. https://doi.org/10.1007/s10195-016-0437-4

6. Hlava N, Niemann CU, Gropper MA, Melcher ML (2009) Postoperative infectious complications of abdominal solid organ transplantation. J Intensive Care Med 24:3–17. https://doi.org/10.1177/088506608327127

7. Martin ET, Kaye KS, Knott C, Nguyen H, Santarossa M, Evans R et al (2016) Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 37:88–99. https://doi.org/10.1017/ice.2015.249

8. Altemeier WA, Culbertson WR, Hummel RP (1968) Surgical considerations of endogenous infections—sources, types, and methods of control. Surg Clin N Am 48:227–240

9. Sganga G, Tascini C, Sozio E, Carlini M, Chirletti P, Cortese F et al (2016) Focus on the prophylaxis, epidemiology and therapy of methicillin-resistant Staphylococcus aureus surgical site infections and a position paper on associated risk factors: the perspective of an Italian group of surgeons. World J Emerg Surg 11:26. https://doi.org/10.1186/s13017-016-0086-1

10. Alexiou K, Drikos I, Terzopoulou M, Sikalas N, Ioannidis A, Economou N (2017) A prospective randomised trial of isolated pathogens of surgical site infections (SSI). Ann Med Surg (Lond) 21:25–29. https://doi.org/10.1016/j.amsu.2017.07.045

11. Nodaras C, Kotsaki A, Tziolos N, Kontopoulou T, Akinosoglou K, Chrisanthakopoulou M et al (2019) Microbiology of acute bacterial skin and skin-structure infections in Greece: a proposed clinical prediction score for the causative pathogen. Int J Antimicrob Agents 54:750–756. https://doi.org/10.1016/j.ijantimicag.2019.08.020

12. Weigelt JA, Lipsky BA, Tabak YP, Derby KG, Kim M, Gupta V (2010) Surgical site infections: causative pathogens and associated outcomes. Am J Infect Control 38:112–120. https://doi.org/10.1016/j.ajic.2009.06.010

13. Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP et al (1985) The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 121:182–205

14. Brandt C, Sohr D, Behnke M, Daschner F, Rüden H, Gastmeier P (2006) Reduction of surgical site infection rates associated with active surveillance. Infect Control Hosp Epidemiol 27:1347–1351. https://doi.org/10.1086/509843

15. Delgado-Rodríguez M, Gómez-Ortega A, Sillero-Arenas M, Llorca J (2001) Epidemiology of surgical-site infections diagnosed after hospital discharge: a prospective cohort study. Infect Control Hosp Epidemiol 22:24–30

16. Huotari K, Lyytikäinen O, Hospital Infection Surveillance Team (2006) Impact of postdischarge surveillance on the rate of surgical site infection after orthopedic surgery. Infect Control Hosp Epidemiol 27:1324–1329

17. Woelber E, Schrick EJ, Gesnser BD, Evans HL (2016) Proportion of surgical site infections occurring after hospital discharge: a systematic review. Surg Infect (Larchmt) 17:510–519. https://doi.org/10.1089/sur.2015.241

18. Bluebell Study Group (2019) Validation of the Bluebelle Wound Healing Questionnaire for assessment of surgical-site infection in closed primary wounds after hospital discharge. Br J Surg 106:226–235. https://doi.org/10.1002/bjs.11008

19. Sartelli M, Pagani L, Iannazzo S, Moro ML, Viale P, Pan A et al (2020) A proposal for a comprehensive approach to infections across the surgical pathway. World J Emerg Surg 15:13. https://doi.org/10.1186/s13017-020-00295-3

20. Fink A, Kosecoff J, Chassin M, Brook RH (1984) Consensus methods: characteristics and guidelines for use. Am J Public Health 74:979–983

21. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 13:606–608

22. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR (1999) Guideline for Prevention of Surgical Site Infection, 1999 Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 27:97–132

23. European Centre for Disease Prevention and Control (2017) Healthcare-associated infections: surgical site infections. In: ECDC. Annual epidemiological report for 2015. Stockholm: ECDC. https://www.ecdc.europa.eu/en/publications-data/health-care-associated-infections-surgical-site-infections-annual-epidemiological. Accessed 12 June 2020

24. European Centre for Disease Prevention and Control (2019) Surveillance of antimicrobial resistance in Europe 2018. Stockholm: ECDC. https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2018.pdf. Accessed 12 June 2020

25. Grundmann H, Glasser C, Albiger B, Aanensen DM, Tomaslin CT, Andreušič AF. European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group et al (2017) Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 17:153–163. https://doi.org/10.1016/S1473-3099(16)30257-2

26. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Burden of AMR Collaborative Group et al (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19:56–66. https://doi.org/10.1016/S1473-3099(18)30065-4

27. Dawson-Hahn EE, Mickan S, Onakpoya I, Roberts N, Kronman VP et al (2018) Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews. Fam Pract 34:511–519. https://doi.org/10.1093/fampra/cmx037

28. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD (2010) Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 340:c2096. https://doi.org/10.1136/bmj.c2096
29. Annoni F, Grimaldi D, Taccone FS (2020) Individualized antibiotic therapy in the treatment of severe infections. Expert Rev Anti Infect Ther 18:27–35. https://doi.org/10.1080/14787210.2020.1696192
30. US Food and Drug Administration, Center for Drug Evaluation and Research (2013) Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Draft Guidance. https://www.fda.gov/media/71052/download. Accessed 12 June 2020
31. Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C (2017) Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 96:1–15. https://doi.org/10.1016/j.jhin.2017.03.004
32. de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB (2009) Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control 37:387–397. https://doi.org/10.1016/j.ajic.2008.12.010
33. Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R et al (2009) Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multicenter matched outcomes study. PLoS ONE 4:e8305. https://doi.org/10.1371/journal.pone.0008305
34. Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C et al (2014) Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents 44:56–64. https://doi.org/10.1016/j.ijantimicag.2014.04.007
35. Restelli U, Bonfanti M, Croce D, Grau S, Metallidis S, Moreno Guíllen S et al (2019) Organisational and financial consequences of the early discharge of patients treated for acute bacterial skin and skin structure infection and osteomyelitis in infectious disease departments in Greece, Italy and Spain: a scenario analysis. BMJ Open 9:e031356. https://doi.org/10.1136/bmjopen-2019-031356
36. Nathwani D, Eckmann C, Lawson W, Solem CT, Corman S, Stephens JM et al (2014) Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe. BMC Infect Dis 14:476. https://doi.org/10.1186/1471-2334-14-476
37. Eells SJ, Nguyen M, Jung J, Macias-Gil R, May L, Miller LG (2016) Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with Staphylococcus aureus skin infections. Antimicrob Agents Chemother 60:2941–2948. https://doi.org/10.1128/AAC.02626-15
38. Stargardt T, Eckmann C, Bouza E, Rossolini GM, Grossi PA (2018) Attitudes of physicians from 10 European countries on adherence and how treatment modalities in ABSSI affect adherence: results from a Delphi survey. Eur J Clin Microbiol Infect Dis 37:1611–1618. https://doi.org/10.1007/s10096-018-3264-0
39. Roberts KD, Sulaiman RM, Rybak MJ (2015) Dalbavancin and oritavancin: an innovative approach to the treatment of gram-positive infections. Pharmacotherapy 35:935–948. https://doi.org/10.1002/phar.1641
40. Sganga G, Tascini C, Sozio E, Colizza S (2017) Early recognition of methicillin-resistant Staphylococcus aureus surgical site infections using risk and protective factors identified by a group of Italian surgeons through Delphi method. World J Emerg Surg 12:25. https://doi.org/10.1186/s13017-017-0136-3

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.